CNTA | Jotup

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

Retrieved on:

Thursday, March 28, 2024

“This is an exciting and pivotal time for Centessa,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.

Key Points:

“This is an exciting and pivotal time for Centessa,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.
Cash, Cash Equivalents and Short-term Investments: $256.5 million as of December 31, 2023, which includes approximately $6.2 million in net proceeds through ATM sales in the fourth quarter ended December 31, 2023.
General & Administrative Expenses: $12.3 million for the fourth quarter ended December 31, 2023, compared to $13.8 million the fourth quarter ended December 31, 2022, and $53.7 million for the full-year 2023 compared to $55.2 million for the full-year 2022.
Net Loss Attributable to Ordinary Shareholders: $36.8 million for the fourth quarter ended December 31, 2023, compared to $43.2 million for the fourth quarter ended December 31, 2022, and $151.1 million for the full-year 2023 compared to $216.2 million for the full-year 2022.

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference

Retrieved on:

Thursday, February 22, 2024

CNTA, Patient, Conference

BOSTON and LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in TD Cowen’s 44th Annual Health Care Conference in Boston, MA.

Key Points:

BOSTON and LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in TD Cowen’s 44th Annual Health Care Conference in Boston, MA.
A fireside chat is scheduled for Tuesday, March 5th at 2:50 PM ET.
The live audio webcast of this event, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations .

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and

Retrieved on:

Friday, February 9, 2024

Society, PWH, Pharmacokinetics, Part, Safety, Haemophilia, ASH, CNTA, APC, Male, Patient, Person, Pharmaceutical industry

The Company previously shared Part 5 results during a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting.

Key Points:

The Company previously shared Part 5 results during a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting.
SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.
“EAHAD provides an exciting opportunity to highlight the therapeutic potential of SerpinPC,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.
“The compelling data from the ongoing Phase 2a study further demonstrate the potential for SerpinPC to be a convenient subcutaneous treatment with a differentiated safety profile for people living with hemophilia.

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on:

Monday, January 22, 2024

CNTA, Patient

BOSTON and LONDON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Key Points:

BOSTON and LONDON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations .

Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference

Retrieved on:

Wednesday, December 13, 2023

Conference, Patient, CNTA

BOSTON and LONDON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Key Points:

BOSTON and LONDON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Saurabh Saha MD PhD, Chief Executive Officer of Centessa, is scheduled to present at the conference on Wednesday, January 10, 2024, at 4:30 PM PST.
The live audio webcast of this event, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations .

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

Retrieved on:

Sunday, December 10, 2023

APC, Thrombin, Haemophilia, ABR, MD, Doctor of Philosophy, Society, ASH, CNTA, Part, Patient, Pharmaceutical industry

The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10, 2023.

Key Points:

The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10, 2023.
SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.
These data highlight the strong foundation on which we are advancing SerpinPC in registrational studies for the treatment of hemophilia B.
We would like to extend our sincere thanks to everyone involved in this study including the patients, investigators, and site coordinators.”
Detailed ABR data from Part 5:

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Retrieved on:

Monday, November 27, 2023

Christian democracy, Family, PDC, Antigen, B cell, Immunology, BDCA2, IND, Autoimmunity, Research, Plasma cell, SLE, Inflammation, Half-life, CD122, SAN, Lupus, GMP, CNTA, Monocyte, Patient, Antigen presentation, Therapy, Vaccine

Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.

Key Points:

Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.
Under the terms of the agreement, Anaptys will receive from Centessa Pharmaceuticals an exclusive, global license for ANB101.
Anaptys will also receive the same rights to ANB102, an extended half-life BDCA2 modulator with the potential to enable quarterly or less frequent dosing.
Centessa is eligible to receive an additional development milestone payment and low single-digit royalties on global net sales.

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

Retrieved on:

Monday, November 13, 2023

Data from Part 5 of the ongoing Phase 2a study accepted for poster presentation at ASH on December 10, 2023.

Key Points:

Data from Part 5 of the ongoing Phase 2a study accepted for poster presentation at ASH on December 10, 2023.
Research & Development Expenses: $28.2 million for the third quarter ended September 30, 2023, compared to $36.7 million for the third quarter ended September 30, 2022.
General & Administrative Expenses: $12.0 million for the third quarter ended September 30, 2023, compared to $12.3 million for the third quarter ended September 30, 2022.
Net Loss Attributable to Ordinary Shareholders: $38.6 million for the third quarter ended September 30, 2023, compared to $53.9 million for the third quarter ended September 30, 2022.

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting

Retrieved on:

Thursday, November 2, 2023

Fibrinolysis, Person, Policy, Haemophilia, Serpin, Society, ASH, Pharmacokinetics, Male, APC, 52 Weeks Make A Year, Part, PWH, Safety, CNTA, Pharmaceutical industry

SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.

Key Points:

SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.
The Phase 2a study (AP-0101) is a first-in-human open-label multicenter study to investigate the safety, tolerability, pharmacokinetics and efficacy of subcutaneous doses of SerpinPC in male participants with severe hemophilia.
The Company has reported results from Parts 1-4, with results from Parts 3 and 4 shared during an oral presentation at ASH on December 10, 2022 .
Centessa plans to make the poster available at https://investors.centessa.com/events-presentations after the session concludes and in accordance with ASH’s embargo policy.

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

Retrieved on:

Tuesday, October 31, 2023

Haemophilia, APC, Safety, Adolescence, Ageing, Patient, CNTA, Development, Pharmaceutical industry

BOSTON and LONDON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced the dosing of the first subject in its registrational PRESent-3 study of SerpinPC for the treatment of hemophilia B with inhibitors.

Key Points:

BOSTON and LONDON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced the dosing of the first subject in its registrational PRESent-3 study of SerpinPC for the treatment of hemophilia B with inhibitors.
The Company began dosing subjects in the registrational PRESent-2 study for the treatment of hemophilia B without inhibitors in July 2023.
SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia B, with or without inhibitors.
Subjects must have undergone a minimum period of prospective observation (at least 12 weeks) under their current therapy before switching to SerpinPC treatment.